Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial
1. 系统已在2025-05-04 14:47:11对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
HJ Kang, S Loftus, A Taylor, C DiCristina…
The Lancet …, 2015
thelancet.com
Background Oral aprepitant, a neurokinin-1 receptor antagonist, is recommended in combination with other anti-emetic agents for the prevention of nausea and vomiting associated with moderately or highly emetogenic chemotherapy in adults, but its efficacy and safety in paediatric patients are unknown. We did this phase 3 trial to examine the safety and efficacy of such treatment in children. Methods In this final analysis of a phase 3, randomised, multicentre, double-blind study, patients aged 6 months to 17 years with a …
